Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

Annals of Oncology

Volumn 26, Issue 3, 2015, Pages 535-541

  Sotelo, M J ^a   Sastre, J ^a   Maestro, M L ^a   Veganzones, S ^a   Vieitez J M ^b   Alonso, V ^c   Gravalos C ^d   Escudero, P ^e   Vera, R ^f   Aranda, E ^g   Garcia Alfonso P ^h   Gallego Plazas, J ⁱ   Lopez, C ^j   Pericay, C ^k   Arrivi, A ^l   Vicente, P ^m   Ballesteros, P ⁿ   Elez, E ^o   Lopez Ladron A ^p   Díaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^f Universidad Pública de Navarra   (Spain)

^g UNIVERSITY OF CÓRDOBA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^j HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^k Centre de Salut Mental   (Spain)

^l HOSPITAL SON LLÀTZER   (Spain)

^m HOSPITAL GENERAL DE GRANOLLERS   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^o HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^p HOSPITAL UNIVERSITARIO DE VALME   (Spain)

more..

Author keywords

Circulating tumor cells; Colorectal cancer; Prognostic marker; Stage III

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CIRCULATING TUMOR CELL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPAIN; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR LOCALIZATION; VERY ELDERLY; BLOOD; CLINICAL TRIAL; COLORECTAL NEOPLASMS; FOLLOW UP; METABOLISM; MIDDLE AGED; PROGNOSIS; TUMOR EMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84926330778     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu568     Document Type: Article

References (20)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
3. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
4. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-6309.
5. Cohen SJ, Punt CJ, Iannotti N et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 1223-1229.
6. Sastre J, Maestro ML, Gómez-España A et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist 2012; 17: 947-955.
7. Sastre J, Maestro ML, Puente J et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008; 19: 935-938.
8. Allen-Mersh TG, McCullough TK, Patel H et al. Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg 2007; 94: 96-105.
9. Uen Y-H, Lu C-Y, Tsai H-L et al. Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol 2008; 15: 2120-2128.
10. Lu C-Y, Uen Y-H, Tsai H-L et al. Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. Br J Cancer 2011; 104: 1178-1184.
11. Gazzaniga P, Gianni W, Raimondi C et al. Circulating tumor cells in high-risk nonmetastatic colorectal cancer. Tumour Biol 2013; 34: 2507-2509.
12. Scholten L, Terstappen LW, van der Palen J et al. Circulating tumor cells as a possible prognostic tool in newly diagnosed nonmetastatic colorectal cancer? J Clin Oncol 2012; 30(Suppl 4): Abst 395.
13. Torino F, Bonmassar E, Bonmassar L et al. Circulating tumor cells in colorectal cancer patients. Cancer Treat Rev 2013; 39: 759-772.
14. Hu CY, Chan W, Delclos GP, Du XL. Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. Am J Clin Oncol 2012; 35: 228-236.
15. Patel H, Le Marer N, Wharton RQ et al. Clearance of circulating tumor cells after excision of primary colorectal cancer. Ann Surg 2002; 235: 226-231.
16. Rack B, Schindlbeck C, Jückstock J et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014; 106: dju066.
17. Wind J, Tuynman JB, Tibbe AG et al. Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. Eur J Surg Oncol 2009; 35: 942-950.
18. Thorsteinsson M, Söletormos G, Jess P. Low number of detectable circulating tumor cells in non-metastatic colon cancer. Anticancer Res 2011; 31: 613-617.
19. Lucci A, Hall CS, Lodhi AK et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012; 13: 688-695.
20. Lu CY, Tsai HL, Uen YH et al. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br J Cancer 2013; 108: 791-797.